JP2020505075A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505075A5
JP2020505075A5 JP2019561375A JP2019561375A JP2020505075A5 JP 2020505075 A5 JP2020505075 A5 JP 2020505075A5 JP 2019561375 A JP2019561375 A JP 2019561375A JP 2019561375 A JP2019561375 A JP 2019561375A JP 2020505075 A5 JP2020505075 A5 JP 2020505075A5
Authority
JP
Japan
Prior art keywords
cancer
seq
antigen
binding portion
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019561375A
Other languages
English (en)
Japanese (ja)
Other versions
JP7169296B2 (ja
JP2020505075A (ja
Filing date
Publication date
Priority claimed from GBGB1701351.7A external-priority patent/GB201701351D0/en
Priority claimed from GBGB1713296.0A external-priority patent/GB201713296D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/050239 external-priority patent/WO2018138521A1/en
Publication of JP2020505075A publication Critical patent/JP2020505075A/ja
Publication of JP2020505075A5 publication Critical patent/JP2020505075A5/ja
Application granted granted Critical
Publication of JP7169296B2 publication Critical patent/JP7169296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019561375A 2017-01-27 2018-01-26 結合剤 Active JP7169296B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1701351.7 2017-01-27
GBGB1701351.7A GB201701351D0 (en) 2017-01-27 2017-01-27 Binding agents
GBGB1713296.0A GB201713296D0 (en) 2017-08-18 2017-08-18 Binding agents
GB1713296.0 2017-08-18
PCT/GB2018/050239 WO2018138521A1 (en) 2017-01-27 2018-01-26 Binding agents

Publications (3)

Publication Number Publication Date
JP2020505075A JP2020505075A (ja) 2020-02-20
JP2020505075A5 true JP2020505075A5 (enExample) 2021-03-11
JP7169296B2 JP7169296B2 (ja) 2022-11-10

Family

ID=61132825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561375A Active JP7169296B2 (ja) 2017-01-27 2018-01-26 結合剤

Country Status (13)

Country Link
US (2) US10457736B2 (enExample)
EP (1) EP3574013A1 (enExample)
JP (1) JP7169296B2 (enExample)
KR (1) KR20190112299A (enExample)
CN (1) CN110475787A (enExample)
AU (1) AU2018213124A1 (enExample)
BR (1) BR112019015453A2 (enExample)
CA (1) CA3051797A1 (enExample)
IL (1) IL268288A (enExample)
MX (1) MX2019008905A (enExample)
RU (1) RU2019125975A (enExample)
SG (1) SG11201906963QA (enExample)
WO (1) WO2018138521A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102123322B1 (ko) 2019-11-01 2020-06-16 주식회사 미래에스엠 상판 오픈형 다용도 선반
KR20210132400A (ko) 2020-04-27 2021-11-04 유미경 다용도 선반
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
CN116782942A (zh) * 2021-02-02 2023-09-19 伊莱利利公司 Gitr拮抗剂和使用其的方法
JP7671092B2 (ja) * 2021-05-10 2025-05-01 メディマブバイオ インコーポレイテッド 抗gitr抗体およびその用途
EP4413036A4 (en) * 2021-10-05 2025-12-03 Lanier Biotherapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST IL-25 AND RELATED USES
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
CN118050505B (zh) * 2024-04-15 2024-06-21 南京佰抗生物科技有限公司 一种多联检荧光免疫层析检测卡

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
AU2015271709B2 (en) * 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer

Similar Documents

Publication Publication Date Title
JP2017535257A5 (enExample)
JP2020531048A5 (enExample)
JP2020528750A5 (enExample)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2021528400A5 (enExample)
JP2020534250A5 (enExample)
JP2020501598A5 (enExample)
JP2020536109A5 (enExample)
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2010535713A5 (enExample)
JP2015535828A5 (enExample)
JP2019532056A5 (enExample)
JP2014524902A5 (enExample)
JP2017521054A5 (enExample)
JP2013502913A5 (enExample)
JP2017512759A5 (enExample)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2020514277A5 (enExample)
JP2009505676A5 (enExample)
RU2019125975A (ru) Связывающие агенты
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
RU2019104980A (ru) Анти-icos антитела
JP2020522281A5 (enExample)
JP2020522280A5 (enExample)
JP2024520666A5 (enExample)